newsfilter
← Latest News
PR Newswire·

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology

  • BioArctic AB has entered a research & collaboration agreement with Eli Lilly to combine BrainTransporter technology with an undisclosed Lilly drug candidate for neurodegeneration.
  • BioArctic will receive a USD 30 million upfront payment.
  • BioArctic is eligible for additional milestone payments totaling up to USD 770 million.
  • BioArctic will earn tiered mid-single digit royalties on future global product sales if the drug reaches the market.
  • BioArctic will generate the new drug candidate while Lilly assumes full responsibility for global development & commercialization.
  • This marks the fourth collaboration for BioArctic using BrainTransporter technology, with BioArctic retaining rights for all other uses.
  • BioArctic is a Swedish biopharma company focused on neurodegenerative diseases & invented Leqembi® in partnership with Eisai.
  • The BrainTransporter platform facilitates active transport of drugs across the blood-brain barrier using the transferrin receptor.
  • The press release includes standard disclaimers regarding investigational status & regulatory approval.
  • The information was disclosed on June 22, 2026, pursuant to the EU Market Abuse Regulation.